CTH-605

CTH-605 is an allogeneic, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Cartherics. It is currently in the preclinical stage of development for the treatment of solid tumors and endometriosis. As an iPSC-derived therapy, CTH-605 is designed to be an "off-the-shelf" product, potentially offering improved scalability and consistency compared to autologous cell therapies. While the specific molecular target of the CAR has not been publicly disclosed by the developer, the therapy utilizes the innate cytotoxic capabilities of NK cells enhanced by a chimeric antigen receptor to specifically identify and eliminate diseased cells associated with cancer and endometriotic lesions.